New Alzheimer's Diagnostics and Drugs Are Reshaping Early Detection and Treatment
Blood-based biomarkers and amyloid-targeting drugs like Lecanemab are transforming how Alzheimer's is caught and treated earlier than ever.
Summary
A 2025 review from UK clinicians synthesizes the latest advances in Alzheimer's disease diagnostics and therapeutics. Blood plasma assays for amyloid beta and phosphorylated tau are making early biomarker detection far more accessible beyond specialized centers. Disease-modifying therapies—notably Lecanemab and Donanemab—target amyloid plaques and show meaningful clinical promise, though they carry risks like amyloid-related imaging abnormalities (ARIA) requiring careful monitoring. The review also highlights evolving understanding of AD pathophysiology, expanding beyond amyloid and tau to include neuroinflammation and oxidative stress as emerging therapeutic targets. Together, these shifts represent a fundamental change in how Alzheimer's is identified and managed, with significant implications for patients and healthcare systems globally.
Detailed Summary
Alzheimer's disease affects millions worldwide, and with aging populations, its prevalence is accelerating. Early diagnosis and disease modification have become urgent priorities, but until recently, reliable tools for either remained limited. This 2025 narrative review from Gloucestershire NHS clinicians synthesizes the current state of both diagnostics and therapeutics for hospital-based clinicians managing AD.
On the diagnostic front, the biggest shift is the growing accessibility of plasma-based biomarker assays. Traditionally, detecting hallmark AD pathology—amyloid beta (Aβ) and phosphorylated tau (p-tau)—required invasive cerebrospinal fluid lumbar punctures or expensive PET neuroimaging. Plasma assays now offer a scalable, less burdensome alternative, potentially enabling earlier and broader population screening.
In therapeutics, the anti-amyloid monoclonal antibodies Lecanemab and Donanemab represent the most significant pharmacological development in decades. Both have demonstrated ability to clear amyloid plaques and slow cognitive decline in early-stage AD. However, both also carry a meaningful risk of ARIA—brain swelling or microbleeds visible on MRI—necessitating rigorous radiological monitoring protocols in clinical practice.
The review also signals a broadening of the AD pathophysiology model. While the amyloid cascade and tau propagation hypotheses remain central, neuroinflammation and oxidative stress are now recognized as important contributors. This opens new therapeutic avenues beyond amyloid clearance, including anti-inflammatory and neuroprotective strategies currently under investigation.
Caveats include that this is a review paper based only on existing literature, and the new DMTs remain approved under restricted criteria, are costly, and require specialist infrastructure. Nonetheless, the convergence of accessible diagnostics and early-intervention therapies marks a genuine inflection point in AD care.
Key Findings
- Plasma-based assays for amyloid beta and p-tau make early AD biomarker detection far more accessible than CSF or PET.
- Lecanemab and Donanemab slow cognitive decline by targeting amyloid but carry ARIA risks requiring MRI monitoring.
- AD pathophysiology models now incorporate neuroinflammation and oxidative stress alongside amyloid and tau.
- Early diagnosis combined with disease-modifying therapies represents a fundamental shift in AD management strategy.
- These advances carry significant implications for healthcare system capacity and resource planning.
Methodology
This is a narrative review published in the British Journal of Hospital Medicine, written for general hospital clinicians. It synthesizes published literature on AD diagnostics and therapeutics without conducting original data collection or meta-analysis. The scope covers biomarker detection methods, approved and emerging drug therapies, and evolving pathophysiological frameworks.
Study Limitations
As a narrative review, this paper is subject to selection bias in the literature it synthesizes and does not provide pooled effect sizes or systematic quality assessment. Access to the full text was unavailable, so specific data points, included studies, and detailed clinical guidance could not be verified. Anti-amyloid DMTs currently have narrow eligibility criteria and limited real-world deployment, which may temper near-term clinical impact.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: